FIELD: medicine, neurology, pharmacy.
SUBSTANCE: invention proposes using levetiracetam and the corresponding levetiracetam-base pharmaceutical composition used in treatment of bipolar disorders, mania and migraine. Also, invention relates to a pharmaceutical composition based on levetiracetam and at least one inhibitor of GABA type A neuronal receptors that is used in treatment of epilepsy, alcohol withdrawal syndrome, tremor, bipolar disorders, obsessive-compulsive disorder, panic state, depression, headache, pain, ischemia and head trauma, to corresponding methods for treatment, to a method for selective enhancing the therapeutic effect of inhibitors of GABA type A neuronal receptors, to a method for treatment of patient with inhibitor of GABA type A neuronal receptors involving the combined administration of indicated inhibitor of GABA type A neuronal receptors with levetiracetam. Invention shows the possibility for using levetiracetam for treatment of chronic and neuropathic pain in lower doses as compared with doses causing secondary effects, and shows its property to enhance activity of inhibitor of GABA type A neuronal receptors.
EFFECT: improved and valuable medicinal properties of agent.
18 cl, 18 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT USING ESLICARBAZEPINE ACETATE OR ESLICARBAZEPINE | 2012 |
|
RU2639120C2 |
| DERIVATIVES OF 2-OXO-1-PYRROLIDINE, METHOD FOR THEIR PREPARING AND USING | 2001 |
|
RU2291860C2 |
| MONOHYDROXYCARBAMAZEPINE FOR MEDICAL PREPARATION FOR AFFECTIVE AND ATTENTION DISORDERS AND NEUROPATHIC PAIN | 2002 |
|
RU2353365C2 |
| ISOVALERAMIDE AS ANTISPATIC AND ANTICONVULSANT AGENT, EXTRACT FROM PLANT OF VALERIANACEACE FAMILY AND HOP AS AGENT FOR TREATMENT OF SPASTICITY SYMPTOM AND METHOD FOR ELIMINATION OF THIS SYMPTOM, METHOD FOR TREATMENT OF PATHOLOGY ELIMINATED BY CENTRALLY-MEDIATED REDUCING MUSCLE TONUS | 1997 |
|
RU2232016C2 |
| THERAPEUTIC USE OF ESLICARBAZEPINE | 2008 |
|
RU2488397C2 |
| DERIVATIVE PYRIDOXIN FOR TREATMENT OF EPILEPSY | 2017 |
|
RU2650523C1 |
| COMPOSITIONS AND METHODS OF PREVENTING AND TREATING ADDICTIONS | 2008 |
|
RU2492858C2 |
| METHODS OF TREATING DRAVET SYNDROME | 2018 |
|
RU2767661C2 |
| 3-BENZYLAMINOMETHYLENEPYRROLIDINE-2,4-DIONE AND ANTICONVULSANT AGENT BASED ON SAID | 1997 |
|
RU2144918C1 |
| METHOD OF TREATING DISEASES, ASSOCIATED WITH REDUCED BDNF PRODUCTION | 2013 |
|
RU2555344C2 |
